Xcout Intel
Oak Hill Bio competitors & alternatives
The 12 closest competitors and alternatives to Oak Hill Bio among biotechnology companies — ranked by similarity to what Oak Hill Bio actually does, not by market-cap band.
Subscribe to see Oak Hill Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Oak Hill Bio
Oak Hill Bio is a clinical-stage biotechnology company focused on acquiring and developing rare disease drugs that have been deprioritized by other organizations. Formed in 2024 as a subsidiary of Oak Hill Bio Holdings, the company operates under the trading name OHB Pediatrics Ltd and is headquartered in Altrincham, United Kingdom.
Oak Hill Bio at a glance
Oak Hill Bio is a biotechnology company headquartered in United States. It has raised at least $39M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $32.5M in June 2026. Xcout tracks 9 named people at Oak Hill Bio, including Josh Distler (Chief Executive Officer).
Oak Hill Bio leadership
- Josh DistlerChief Executive Officer
- Sharon MorrissChief Operating Officer
- Ike GreensteinChief Financial Officer
- Brenda VincenziChief Medical Officer
- Doug FambroughBoard Member
- Josh DistlerBoard Member
3 more named people on record for Oak Hill Bio, with roles, board committees and tenure — see the full roster →
Oak Hill Bio funding rounds
At least $39M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $32.5M | 4 named | |
| Series A | $6.5M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Oak Hill Bio competitors
Ranked by semantic similarity — how close each company is to Oak Hill Bio by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Orchard Therapeutics plc is a biopharmaceutical company with operations including a U.S. headquarters located in Boston, Massachusetts.
Similar biotechnology company
Ollin Biosciences is a clinical-stage biopharmaceutical holding company established in 2023 and headquartered in Austin, Texas, dedicated to developing therapeutics.
Similar biotechnology company
Tempero Bio, Inc. is a clinical-stage biopharmaceutical holding company established in 2020 and headquartered in Oakland, California. The company focuses on developing transformative therapeutics and advancing its drug pipeline through clinical trials.
Biotech
Healx is an AI-native pharmaceutical company that uses artificial intelligence and technology to discover and develop new treatments for rare diseases. The company redevelops, combines, and enhances known compounds to build a drug pipeline aimed at delivering effective therapies to patients.
Biotech
Oxford Biomedica plc is a biopharmaceutical firm focused on the discovery, advancement, and sophisticated bioprocessing of innovative cell and gene therapies. Operating globally, with a strong presence across Europe, the company organizes its activities into two segments: Platform and Product. Its proprietary LentiVector platform technology facilitates the integration of genes into non-dividing cells, such as neurological cells in the brain and retinal cells in the eye, and can incorporate diverse therapeutic genes. The company's developmental pipeline includes promising candidates like Axo-Lenti-PD, a gene-based treatment for Parkinson's disease. Other pre-clinical stage programs feature OXB-302, targeting haematological tumors, and OXB-401, OXB-40X, and OXB-40Y, all addressing liver indications. Oxford Biomedica maintains numerous strategic alliances with prominent pharmaceutical entities such as Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and the Vaccines Manufacturing and Innovation Centre. Additionally, it engages in research collaborations, including a partnership with Circularis Biotechnologies to identify novel tissue-specific promoters for in vivo lentiviral gene therapy, Virica Biotech for scaling viral medicines, Isolere Bio for enhancing downstream manufacturing efficiencies of biologics, and BiologIC Technologies for utilizing a novel biocomputer system in viral vector development. Founded in 1995, Oxford Biomedica plc is headquartered in Oxford, United Kingdom.
Life Sciences
Hawkhill Therapeutics Ltd is a biotech spin-out company from Tay Therapeutics based in Dundee, UK, focusing on scientific research and the delivery of new therapies.
Similar biotechnology company
Aeglea BioTherapeutics, Inc. is a clinical-stage biopharmaceutical company that has been involved in developing therapeutics and acquiring other ventures.
Similar biotechnology company
Cadenza Bio, Inc. is a privately held preclinical biotechnology company founded in 2022 and headquartered in Oklahoma City, dedicated to developing novel, non-steroidal, highly selective small-molecule therapies.
Biotech
Octant Bio is a biotechnology company that combines next-generation biology, chemistry, and computation to discover and develop precision small molecule therapeutics. The company targets complex cellular mechanisms to address genetic diseases, such as protein misfolding and mistrafficking across various therapeutic areas including genetic disorders, oncology, metabolism, and immunology.
Similar biotechnology company
Pathios Therapeutics Limited is a biotech company established in 2017 and registered in England and Wales, focusing on the discovery and development of first-in-class therapies.
Biotech
Ocean Biomedical, Inc. operates as a biopharmaceutical firm committed to identifying and advancing novel therapeutic solutions for various medical challenges, including cancer, fibrotic disorders, infectious illnesses, and inflammation. The company's pipeline includes the development of both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are specifically designed to target Chi3l1, offering potential treatments for non-small cell lung cancer and glioblastoma multiforme. Additionally, they are progressing a small molecule drug candidate aimed at Chit1, intended to address Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Leveraging its proprietary WPDS platform, Ocean Biomedical is also developing three further product candidates. These encompass a promising malaria vaccine, a humanized mAb therapeutic for malaria that targets the Plasmodium falciparum glutamic-acid-rich protein (PfGARP), and a small molecule malaria therapeutic also designed to interact with PfGARP. Furthermore, a treatment candidate for hospitalized COVID-19 patients is also under development. The company, established in 2019, maintains its operations in Providence, Rhode Island.
Similar biotechnology company
Alchemab Therapeutics Ltd is a biotechnology company headquartered in London, England, focused on pioneering patient-centric antibody discovery and development.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Oak Hill Bio and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Oak Hill Bioand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →